Revolution Medicines (RVMD) Could Be 8% Overvalued As FTSE All World Inclusion Draws Focus

Revolution Medicines (RVMD) was added to the FTSE All-World Index on 19 September 2026, an inclusion that can draw fresh attention as index-tracking funds realign portfolios and adjust exposure.

Trading around US$205.89, Revolution Medicines has seen short-term share price momentum cool slightly over the past month after a strong 90-day share price return. At the same time, a very large 1-year total shareholder return points to powerful longer-term enthusiasm building around the story.

See how Revolution Medicines fits alongside other high momentum stories being tracked by funds after index changes with our curated list of 19 high quality undiscovered gems.

Revolution Medicines now carries both strong long-term share price momentum and fresh index-linked attention. The harder question is whether that enthusiasm already overprices the business or still leaves meaningful upside on the table.

Most Popular Narrative: 8% Overvalued

Against a last close of $205.89, the most widely followed narrative pegs Revolution Medicines’ fair value at about $190.52. This frames today’s price as modestly ahead of those assumptions while still hanging a lot on future execution in RAS-driven cancers.

The assumed bearish price target for Revolution Medicines is $190.52, which represents up to two standard deviations below the consensus price target of $257.47. This valuation is based on what can be assumed as the expectations of Revolution Medicines's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.

See why 3 investors see Revolution Medicines as 8% overvalued.

Result: Fair Value of $190.52 (OVERVALUED)

Still, if RASONQUE gains wider adoption in pancreatic and lung cancer, or if the BeOne regional partnership scales smoothly, the cautious Revolution Medicines narrative could be tested quickly.

Find out about the key risks to this Revolution Medicines narrative.

Another View: SWS DCF Model Flips The Verdict

The bearish fair value narrative for Revolution Medicines sits at $190.52 and tags the stock as 8% overvalued. Our DCF model presents a different view. It points to a future cash flow value of $857.71, which is about 76% above the current $205.89 share price.

If the analyst-based scenario is nudging you toward caution, the SWS DCF model raises a sharper question. Is the market already capturing the risks around execution, or is it underestimating the cash flow potential that sits behind Revolution Medicines’ RAS portfolio?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 28 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on Revolution Medicines so far. If that tension is pushing you to act, stress test the enthusiasm and concern yourself by weighing the 3 key rewards and 2 important warning signs.

Looking for more Revolution Medicines investment ideas?

If the debate around Revolution Medicines has sparked fresh curiosity, do not stop here. Use focused screeners to spot new opportunities that match your style.

• Target resilient compounding potential by scanning a 31 resilient stocks with low risk scores list that filters for businesses with steadier risk profiles and fewer balance sheet surprises.
• Hunt for quality at a discount with the 28 high quality undervalued stocks and see which stocks combine stronger fundamentals with prices that lag those characteristics.
• Build a watchlist of cash flow support by checking the 7 dividend fortresses that highlights companies prioritising consistent shareholder payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com